The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand
Andersson KM, Stover J. Vaccine. 2011 Jun 22. [Epub ahead of print]
Although published data from the recent ALVAC/AIDSVAX trial in Thailand (RV144) indicated that the HIV vaccine provided very modest protection overall (31.2%), new analysis of trial data has suggested higher efficacy levels earlier in the follow-up period. CDC and UNAIDS organised several modelling research teams to explore the implications of the trial results and potential utility of this vaccine. Andersson and Stover explored the impact of a vaccine with moderate but rapidly waning protection (78%, 1.43 years) using an exponential decay function fit to trial data. They varied programme coverage levels (20-80%), vaccine efficacy (30-90%), timing (single or multi-year programmes), prioritisation (general or populations at higher risk), and background levels of all other prevention programmes (constant or scaled-up). They simulated these various vaccination scenarios in two representative countries using demographic projections generated with Spectrum modelling software. They assumed the vaccine becomes available in 2020 and target coverage is achieved by 2025. A general vaccination strategy in South Africa covering 60% of the population, for example, would prevent 3.0 million infections between 2020 and 2030—36% of expected infections—and would be very effective, requiring only 39 vaccinations/infection averted. The same strategy in Thailand would prevent 81,000 infections—35% of expected infections—but would require 1725 vaccinations/infection averted. Prioritising only populations at higher risk of exposure in Thailand would reduce total vaccinations given by more than ten-fold and would still prevent 52,000 infections—23% of expected infections—while requiring only 220 vaccinations/infection averted. Outcomes were sensitive to programme coverage, vaccine efficacy, and background levels of all other prevention programmes. A vaccine with rapidly waning protection could have a substantial impact on the epidemic in South Africa and Thailand. Due to the short duration of effect, large numbers of vaccinations would be needed to maintain high population coverage levels. Further research into the immunological effects of booster vaccinations is warranted.
For abstract access click here
Editor’s note: In October 2009, the RV144 prime-boost vaccine trial in a large community-based trial in Thailand reported modest protection at 42 months—a 31% reduction with a wide confidence interval of 1%-51%. Some people doubted these findings but at AIDS Vaccine 2011 conference held this month in Thailand, the results of joint efforts across the vaccine field showing immunological correlates of protection were reported to scientific acclaim. This means that we understand better now why the vaccine protected some people. These results brought the work of the CDC/UNAIDS vaccine modelling consensus group, launched in a dedicated issue of VACCINE at the conference, into sharp focus. [You can download the entire issue at http://www.sciencedirect.com/science/journal/0264410X/29/36]. We invited modelling groups to assess the impact of an RV144-like partially protective vaccine, basing their models on data showing that vaccine efficacy had been 60% at 12 months, waning thereafter, and estimating the effects over a 10-year period of a single mass vaccination of 30% and 60% of sexually active adults. For settings such as Thailand, the USA, South Africa, and Australia, they found that RV144-like vaccines would have modest impact, averting 5-15% of infections over 10-year periods, especially in countries with high incidence. Vaccination with the complete prime-boost regimen would be cost-effective at 150 US$ per person in South Africa and at 500 US$ in the USA. The Andersson-Stover modelling team found that the number of vaccinations required to avert one HIV infection with a programme starting in 2020 varied by setting and could be improved with prioritisation of sub-populations at higher risk of HIV exposure. Plans are underway now to study the effects of a booster dose on immune responses, to conduct a trial in Thailand among men who have sex with men, and to conduct a trial in South Africa using clade C inserts rather than the B/E inserts that were used in RV144 regimen to match circulating Thai HIV subtypes. We are on our way!